Merck Scores As Judge Spurns New Fosamax Class

Law360, New York (January 4, 2008, 12:00 AM EST) -- Despite months of plaintiffs' lobbying, the federal judge overseeing the Fosamax product liability litigation against pharmaceutical giant Merck & Co. has declined to grant class status to patients who have not yet developed a painful jaw condition allegedly linked to the osteoporosis medication.

On Thursday, Judge John Keenan of the U.S. District Court for the Southern District of New York batted down a motion by patients in Florida, Pennsylvania and Louisiana, maintaining that a class action would not be the proper way to pursue its bid...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.